ࡱ> BA g2ɀ\pEvans Gillian (Human Resources) Ba==xl)18X@"1RCalibri1RCalibri1RCalibri1RCalibri1 RArial1RCalibri1 RCalibri1RCalibri14RCalibri1 RCalibri1RCalibri1RCalibri1,8RCalibri18RCalibri18RCalibri1>RCalibri14RCalibri1<RCalibri1?RCalibri1h8RCambria1RCalibri1 RCalibri18RCalibri1RArial1RArial1RArial1RArial""#,##0;\-""#,##0""#,##0;[Red]\-""#,##0""#,##0.00;\-""#,##0.00#""#,##0.00;[Red]\-""#,##0.005*0_-""* #,##0_-;\-""* #,##0_-;_-""* "-"_-;_-@_-,)'_-* #,##0_-;\-* #,##0_-;_-* "-"_-;_-@_-=,8_-""* #,##0.00_-;\-""* #,##0.00_-;_-""* "-"??_-;_-@_-4+/_-* #,##0.00_-;\-* #,##0.00_-;_-* "-"??_-;_-@_-"Yes";"Yes";"No""True";"True";"False""On";"On";"Off"],[$ -2]\ #,##0.00_);[Red]\([$ -2]\ #,##0.00\)                                                                       ff + ) , *     P  P        `            a>   8@ @  8@ @  8@ @  8@ @  8 x@ @  x@ @  8 ||GSC'}-} 00_)}-} 00_)}-} 00_)}-} 00_)}-} 00_)}-} 00_)}-} 00_)}-} 00_)}-} 00_)}-}  00_)}-}  00_)}-}  00_)}-}  00_)}-}  00_)}-} 00_)}-} 00_)}A} 00_)ef[$ -}A} 00_)ef[$ -}A} 00_)ef[$ -}A} 00_)ef[$ -}A} 00_)ef[$ -}A} 00_)ef [$ -}A} 00_)L[$ -}A} 00_)L[$ -}A} 00_)L[$ -}A} 00_)L[$ -}A} 00_)L[$ -}A} 00_)L [$ -}A} 00_)23[$ -}A} 00_)23[$ -}A} 00_)23[$ -}A} 00_)23[$ -}A}  00_)23[$ -}A}! 00_)23 [$ -}A}" 00_)[$ -}A}# 00_)[$ -}A}$ 00_)[$ -}A}% 00_)[$ -}A}& 00_)[$ -}A}' 00_) [$ -}A}( 00_)[$ -}}) }00_)[$ -##0.  }}* 00_)[$ -???##0.??? ??? ???}-}+ 00_)}-}, 00_)}-}- 00_)}-}. 00_)}-}/ 00_)}A}0 a00_)[$ -}A}1 00_)[$ -}A}2 00_)?[$ -}A}3 00_)23[$ -}-}4 00_)}}5 ??v00_)̙[$ -##0.  }A}6 }00_)[$ -}A}7 e00_)[$ -}}8 00_)[$ -##0.  }}9 ???00_)[$ -???##0.??? ??? ???}-}: 00_)}-}; 00_)}U}< 00_)[$ -##0.}-}= 00_)}-}> I}00_)}(}? 00_)}(}@ 00_)}(}A 00_)}(}B 00_)}(}C 00_)}<}D 00_)ef[$}<}E 00_)ef[$}(}F 00_) 20% - Accent1M 20% - Accent1 ef % 20% - Accent2M" 20% - Accent2 ef % 20% - Accent3M& 20% - Accent3 ef % 20% - Accent4M* 20% - Accent4 ef % 20% - Accent5M. 20% - Accent5 ef % 20% - Accent6M2 20% - Accent6  ef % 40% - Accent1M 40% - Accent1 L % 40% - Accent2M# 40% - Accent2 L渷 % 40% - Accent3M' 40% - Accent3 L % 40% - Accent4M+ 40% - Accent4 L % 40% - Accent5M/ 40% - Accent5 L % 40% - Accent6M3 40% - Accent6  Lմ % 60% - Accent1M 60% - Accent1 23 % 60% - Accent2M$ 60% - Accent2 23ږ % 60% - Accent3M( 60% - Accent3 23כ % 60% - Accent4M, 60% - Accent4 23 % 60% - Accent5M0 60% - Accent5 23 %! 60% - Accent6M4 60% - Accent6  23 % "Accent1AAccent1 O % #Accent2A!Accent2 PM % $Accent3A%Accent3 Y % %Accent4A)Accent4 d % &Accent5A-Accent5 K % 'Accent6A1Accent6  F %(Bad9Bad  %) Calculation Calculation  }% * Check Cell Check Cell  %????????? ???+ Comma,( Comma [0]-&Currency.. Currency [0]/Explanatory TextG5Explanatory Text % 0Good;Good  a%1 Heading 1G Heading 1 I}%O2 Heading 2G Heading 2 I}%?3 Heading 3G Heading 3 I}%234 Heading 49 Heading 4 I}% 5InputuInput ̙ ??v% 6 Linked CellK Linked Cell }% 7NeutralANeutral  e%3Normal % 8Noteb Note   9OutputwOutput  ???%????????? ???:$Percent ;Title1Title I}% <TotalMTotal %OO= Warning Text? Warning Text %XTableStyleMedium2PivotStyleLight16`7Patients treated ,8''Number of patients treatedRheumatoid ArthritisAnkylosing SpondylitisPsoriatic Arthritis PsoriasisCrohns Disease-Extra patients treated within WWL wards/deptsTOTAL+100 inpatients - don t keep indication dataAbatacept (Orencia)Adalimumab (Biosimilar)Adalimumab (Humira)Apremilast (Otezla)*13 inpatients - don t keep indication dataBaricitinib (Olumiant)Brodalumab (Kyntheum)Certolizumab (Cimzia)Dimethyl Fumarate (Skilarence))8 inpatients - don t keep indication dataEtanercept (Enbrel)*Etanercept Biosimilar (Benepali or Erelzi)Golimumab (Simponi)Guselkumab (Tremfya)Infliximab (Remicade)*17 inpatients - don t keep indication data5Infliximab Biosimilar (Inflectra, Remsima or Flixabi)Ixekizumab (Taltz)Rituximab (Mabthera)*Rituximab Biosimilar (Rixathon or Truxima)Sarilumab (Kevzara)Secukinumab (Cosentyx)Tildrakizumab (Ilumetri)Tocilizumab (Ro Actemra)Tofacitinib (Xeljanz)Ustekinumab (Stelara)*15 inpatients - don t keep indication dataVedolizumab (Entyvio)*47 inpatients - don t keep indication data0Ulcerative Cloitis? Answered as presumed Colitis *1 G2345IccB g2ɀ U`  dMbP?_*+%,&ffffff?'ffffff?(?)?M\\WWLXerPS1\Xerox_Follow_You0C 4dXXA4 (210 x 297 mm)DINU"D~SMTJXerox PullPrn PCL6 V4.0.548.8.0RESDLLUniresDLLXrxTrueTypeFontDlOptionTTF_DOWNLOAD_AS_TRUETYPEXrxEdgeToEdgeEDGE_TO_EDGE_OFFColorMode24bppXrxHalftoneXRX_NORMAL_HTXEROX_JOB_SETUP_BEGINCBXEROX_JOB_SETUP_ENDCBXEROX_DOC_BEGINCBXEROX_DOC_SETUP_ENDCBXEROX_PAGE_SETUP_BEGINCBXEROX_PAGE_SETUP_ENDCBXEROX_PAGE_FINISH_BEGINCBXEROX_PAGE_FINISH_ENDCBXEROX_DOC_FINISH_BEGINCBXEROX_DOC_FINISH_ENDCBXEROX_JOB_FINISH_BEGINCBXEROX_JOB_FINISH_ENDCBOrientationPORTRAITCollateONDuplexVERTICALResolutionRes600x600PaperSizeA4D1NRX >6   MSCF,90R)//Uncompressed-Data//uR3)CKZklU>;---: mCv ӇliKDi-P(BĀC>W V A &&D21=nY~{vo=;-+_Q˴[ RV*ՂiDZj4'>kdn @ԎLts0^J4RJZ|Y;g(^HO&n3w`~^S8B.z4to^0ݛKK#kzrY ayB;"ug@ UqgGk#3 1ka}$ OgNR&=0`8Y\\*,:O`Qhvt9E/3-2a19cF'rB I*W_<9=MUDnS5uQ FL \vu6CpJ¡ٵxQnej ث3,qb9Wnm9TBsT[! 6v|yyTP I{A:Ū\0'Y^X ߴAg S9VsF7Cp%` -v'E=%?i;/83_"V~m$/xdtM|ڄHa]m0֊W-qU~Td]N#+KuDw:7{wAW}Kqr ӬS̗sW*Vs3n8)BMȜ ^/¼*F=t >īDr8et:CcbgZN˨doX8G4m )n~+{Y boWxUW;qpve^*w /q$X1>Fj0;$u!j+V4P/kSTڂy1D Fd^\РRG Tdxqt\oesZ w{pk8N@^?iL6.6 +,=n]Qd vw\ٝtHR4[GDv҂äNyi{م3iy!-]sH gWCZ5< pJFFFJFFFJFFFFJFFFFFFFFFJJ>@   ggD Oh+'0@Hp  Evans Gillian (Human Resources) Evans Gillian (Human Resources)Microsoft Excel@=ْ@ '*?՜.+,0 PXd lt| WWL Patients treated  Worksheets  !"#$%&'()*+,-./02345678:;<=>?@Root Entry FWorkbook`SummaryInformation(1DocumentSummaryInformation89